FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.
What happened
FDA reviewed Intimate Rose's website in August 2025 and found it offered compounded semaglutide and tirzepatide drug products. The site claimed these products had the "same active ingredient as Ozempic and Wegovy" and "same active ingredient as Mounjaro and Zepbound." FDA said those claims are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claimed compounded semaglutide had the same active ingredient as Ozempic and Wegovy, which FDA says falsely implies it is the same as FDA-approved drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claimed compounded tirzepatide had the same active ingredient as Mounjaro and Zepbound, which FDA says falsely implies it is the same as FDA-approved drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the misleading claims make the compounded drugs misbranded, meaning falsely promoted, and shipping them across state lines is prohibited.
FDCA section 301(a) [21 U.S.C. § 331(a)]The letter also says receiving misbranded drugs in interstate commerce is illegal.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Intimate Rose to immediately stop using the misleading claims and to respond in writing within 15 working days describing the specific steps taken to fix the violations and prevent recurrence, with supporting documents.
Who should pay attention
- online telehealth sellers of compounded GLP-1 drugs
- compounding pharmacies that advertise semaglutide or tirzepatide
- compliance teams reviewing drug marketing claims
This is a summary. Read the original letter on fda.gov.